Evidence map›Paper›PMID 29178920›Full record

ArticleMicrobiome2017

The gut mycobiome of the Human Microbiome Project healthy cohort.

Andrea K Nash, Thomas A Auchtung, Matthew C Wong, Daniel P Smith, Jonathan R Gesell, Matthew C Ross, Christopher J Stewart, Ginger A Metcalf, Donna M Muzny, Richard A Gibbs and 2 more

Registry-linked trialAbstract read
In one paragraph

Article in Microbiome, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06992453 (Disentangling Microbiome Engraftment by Multi-omics of the Gut Ecosystem During Fecal Transplant), which is not on this map. Cited by 595 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
595citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06992453 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Disentangling Microbiome Engraftment by Multi-omics of the Gut Ecosystem During Fecal Transplant

TypeinterventionalSponsorCatholic University of the Sacred HeartRan2026 to 2029Enrolled90ConditionsRecurrent C. Difficile (rCDI), Ulcerative Colitis (UC), Metabolic Syndrome (MetS)ArmsFecal microbiota transplantation (FMT)
3 · Its place in the literature

Who cites it

595 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Virulence · 2026
    Article
  7. Article
  8. Observational
  9. Article
  10. Review
  11. Article
  12. Observational
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

535 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Andrea K NashAlkek Center for Metagenomics and Microbiome Research, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
Thomas A AuchtungAlkek Center for Metagenomics and Microbiome Research, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
Matthew C WongAlkek Center for Metagenomics and Microbiome Research, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
Daniel P SmithAlkek Center for Metagenomics and Microbiome Research, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
Jonathan R GesellAlkek Center for Metagenomics and Microbiome Research, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
Matthew C RossAlkek Center for Metagenomics and Microbiome Research, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
Christopher J StewartAlkek Center for Metagenomics and Microbiome Research, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
Ginger A MetcalfHuman Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA.
Donna M MuznyHuman Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA.
Richard A GibbsHuman Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA.
Nadim J AjamiAlkek Center for Metagenomics and Microbiome Research, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
Joseph F PetrosinoAlkek Center for Metagenomics and Microbiome Research, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA. jpetrosi@bcm.edu.

Funding

The Human Genome Sequencing CenterU54HG003273 · NHGRI · BAYLOR COLLEGE OF MEDICINE · PI GIBBS, RICHARD A · 2004 to 2015
$341.3M
Tissue Analysis & Molecular Imaging CoreP30DK056338 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI Geoffrey A Preidis · 2001 to 2026
$28.3M
National Human Genome Research Institute 2 U54 HG003273NHGRI NIH HHS U54 HG003273NIDDK NIH HHS P30 DK056338
6 · The paper itself

Abstract

backgroundMost studies describing the human gut microbiome in healthy and diseased states have emphasized the bacterial component, but the fungal microbiome (i.e., the mycobiome) is beginning to gain recognition as a fundamental part of our microbiome. To date, human gut mycobiome studies have primarily been disease centric or in small cohorts of healthy individuals. To contribute to existing knowledge of the human mycobiome, we investigated the gut mycobiome of the Human Microbiome Project (HMP) cohort by sequencing the Internal Transcribed Spacer 2 (ITS2) region as well as the 18S rRNA gene.

resultsThree hundred seventeen HMP stool samples were analyzed by ITS2 sequencing. Fecal fungal diversity was significantly lower in comparison to bacterial diversity. Yeast dominated the samples, comprising eight of the top 15 most abundant genera. Specifically, fungal communities were characterized by a high prevalence of Saccharomyces, Malassezia, and Candida, with S. cerevisiae, M. restricta, and C. albicans operational taxonomic units (OTUs) present in 96.8, 88.3, and 80.8% of samples, respectively. There was a high degree of inter- and intra-volunteer variability in fungal communities. However, S. cerevisiae, M. restricta, and C. albicans OTUs were found in 92.2, 78.3, and 63.6% of volunteers, respectively, in all samples donated over an approximately 1-year period. Metagenomic and 18S rRNA gene sequencing data agreed with ITS2 results; however, ITS2 sequencing provided greater resolution of the relatively low abundance mycobiome constituents.

conclusionsCompared to bacterial communities, the human gut mycobiome is low in diversity and dominated by yeast including Saccharomyces, Malassezia, and Candida. Both inter- and intra-volunteer variability in the HMP cohort were high, revealing that unlike bacterial communities, an individual's mycobiome is no more similar to itself over time than to another person's. Nonetheless, several fungal species persisted across a majority of samples, evidence that a core gut mycobiome may exist. ITS2 sequencing data provided greater resolution of the mycobiome membership compared to metagenomic and 18S rRNA gene sequencing data, suggesting that it is a more sensitive method for studying the mycobiome of stool samples.

Indexed as

Healthy VolunteersMicrobiotaMycobiomeCandidaCohort StudiesDNA, Ribosomal SpacerFecesFungiGastrointestinal MicrobiomeGenetic VariationHigh-Throughput Nucleotide SequencingHumansMalasseziaMetagenomicsRNA, Ribosomal, 18SSaccharomycesDNA, Ribosomal SpacerRNA, Ribosomal, 18SFecal microbiomeFungal microbiomeFungiHMPITS2MetagenomicsMicrobiomeMicrobiotaThere was a high degree o Spacer

Identifiers

PMID29178920
PMCPMC5702186

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.